India's Orchid Pharma rises for 4th day after US FDA completes facility check

Orchid Pharma

25/02/2025 07:16

** India's Orchid Pharma  ORCD.NS  locked in 5% upper
circuit for fourth consecutive session
    ** Stock up 23.7% in five days, on course for longest
winning streak of 2025
    ** Company's Alathur API facility successfully completed US
FDA inspection, remains India's only US regulator-approved
facility for antibiotic drug Sterile Cephalosporins, it said
after market hours on February 19
    ** Stock still down around 28% so far in February on poor Q3
earnings and overall weakness in pharma  .NIPHARM  stocks
    ** API and formulations maker down 44% so far in 2025 vs
13.5% drop in .NIPHARM  
    

 (Reporting by Vivek Kumar M)
 ((VivekKumar.M@thomsonreuters.com;))